ANAVEX LIFE SCIENCES CORP.
51 W. 52nd Street, 7th Floor
New York, NY 10019-6163
June 9, 2017
VIA EDGAR
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Attn: Hillary Daniels
| Re: | Anavex Life Sciences Corp. | |
| Request for Acceleration of Registration Statement on Form S-3 | ||
| File No. 333-218292 | ||
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Anavex Life Sciences Corp., a Nevada corporation (the “Company”), hereby requests acceleration of the effectiveness of its Registration Statement on Form S-3 (File No. 333-218292), filed with the U.S. Securities and Exchange Commission on May 26, 2017, to 4:00PM ET on June 12, 2017 or as soon thereafter as practicable.
Please direct any questions or comments regarding this filing to Clayton Parker, Esq. at (305) 794-6293 of K&L Gates LLP, legal counsel to the Company.
| Sincerely, | |
| /s/ Christopher Missling, PhD | |
Christopher Missling, PhD Chief Executive Officer |
